V
VIRTUE Diagnostics
A leading innovative global diagnostic company by leveraging diverse technology platforms through internal development and external collaboration
About VIRTUE Diagnostics
Virtue Diagnostics, operating under the website virtuedx.com, is an innovative in-vitro diagnostic (IVD) company that specializes in the detection and management of infectious diseases, cancer, and chronic diseases. The company's primary focus is on the development and application of advanced diagnostic technologies, providing clinical solutions for patients at all stages of disease, from early screening to treatment monitoring and minimal residual disease management.
The company operates in the global healthcare market, with a particular emphasis on China and other emerging markets. Its business model is centered on leveraging diverse technology platforms through both internal development and external collaboration. This approach has allowed Virtue Diagnostics to establish a complete industrial chain, from innovative research and development to clinical trials, clinical applications, and large-scale industrialization.
Virtue Diagnostics' revenue is primarily generated through the sale of its diagnostic products and services. The company has also successfully raised significant capital through investment rounds, such as the $100 million Series B funding round it closed in September 2023.
In recent years, Virtue Diagnostics has made significant strides in its market, including the acquisition of Labtest Diagnostics in Brazil and the successful showcasing of its Clinical MS Technology and QSight 420MD. The company has also been recognized for its contributions to the IVD industry, receiving the 2023 Best IVD Enterprise Award.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Pudong, China
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2022 | $100M | $400M | Oriza Holdings · PerkinElmer · Lilly Asia Ventures · HongShan | ↗ |
| SERIES AOther financing | Dec 2020 | $30M | $120M | Lilly Asia Ventures · PerkinElmer | — |
Growth signals
Latest recorded traffic for VIRTUE Diagnostics is 370 monthly website visits, down 76.9% over the last three months. VIRTUE Diagnostics's team declined 10% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Lilly Asia Ventures
PerkinElmer
Sequoia
Morningside
Oriza Holdings
HongShan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VIRTUE Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VIRTUE Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.